The conversion is a mechanical step following the previously announced special dividend. Monitor the next 10-Q for any impact on earnings per share from the increased share count.
JAGX drugs
JAGX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $0.5575entry
- T+1 · 18d ago −10.53%α −12.18% · $0.4988
- T+5 · 12d ago −21.67%α −21.08% · $0.4367
- T+13 · todayOpen
- T+20 · in 10d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Jaguar Health reports the automatic conversion of its Series R Convertible Preferred Stock into common stock on November 2, 2026, resulting in 13,345,986 common shares outstanding. This is a routine capital structure event following a previously disclosed special dividend and has no direct financial impact on operations.
Key Facts
- On November 2, 2026, each outstanding share of Series R Convertible Preferred Stock automatically converted into five shares of common stock.
- Immediately after conversion, there were 13,345,986 shares of common stock issued and outstanding.
- Holders of Eligible Warrants are entitled to receive up to 69,823 shares of common stock upon exercise.
- The Series R Preferred Stock was issued as a special one-time dividend on October 15, 2026, to common stockholders and certain warrant holders of record on October 13, 2026.
Financial Impact
No cash impact; conversion of preferred stock into common stock with no stated change in total equity value.
Risk Factors
- Potential dilution from the conversion of preferred stock and exercise of warrants, though the number of additional shares is relatively small given the current share count.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-445055 |
| Document: 0001193125-26-445055-index-headers.html | 0001193125-26-445055 |
| Document: 0001193125-26-445055-index.html | 0001193125-26-445055 |
| Document: 0001193125-26-445055.txt | 0001193125-26-445055 |
Track record
33 reports on JAGX
7 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +97.54% at T+1 after the Apr 27, 2026 report. 21 of 23 went positive at some point.
Filters
- Nov 20, 20261d ago 8-K Bearish 5/10 Entry $0.2877 Now $0.2270 +21.10% settles Feb 19
- Nov 16, 20265d ago 8-K Bearish 6/10 Entry $0.3864 Now $0.2270 +41.25% settles Feb 12
- Nov 9, 202612d ago 424B5 Bearish 6/10 Entry $0.4361 Now $0.2270 +47.95% settles Feb 5
- Nov 6, 202615d ago 8-K Bearish 6/10 Entry $0.4361 Now $0.2270 +47.95% settles Feb 5
- Nov 6, 202616d ago EFFECT Bearish 5/10 Entry $0.4043 Now $0.2270 +43.85% settles Feb 4
- Nov 3, 202618d ago S-3/A Bearish 5/10 Entry $0.5575 Now $0.2270 +59.28% settles Feb 1
- Nov 3, 202618d ago 8-K Neutral 2/10 Viewing Entry $0.5575 Now $0.2270 −59.28% settles Feb 1
- Oct 29, 202623d ago DEFA14A Bearish 6/10 Entry $2.04 Now $0.2270 +88.87% settles Jan 27
- Oct 28, 202624d ago 8-K Neutral 2/10 Entry $2.04 Now $0.2270 −88.87% settles Jan 27
- Oct 22, 20264w ago S-3 Bearish 5/10 Entry $2.04 Now $0.2270 +88.87% settles Jan 21
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers